サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566901

免疫学市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2024年～2033年

Immunology Market By Product Type, By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 231 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
免疫学市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2024年～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 231 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

免疫学市場

免疫学市場の2023年の市場規模は1,101億米ドルで、2024年から2033年までのCAGRは6.3%で、2033年には2,040億米ドルに達すると予測されています。

免疫学は、生物の免疫システムを研究する科学の一分野です。免疫システムは、感染症、異物、病気と闘う生体の防御機構です。免疫学は、腫瘍学、臓器移植、リウマチ学、細菌学、ウイルス学、寄生虫学、皮膚科学、精神医学など、医学の多様な分野で応用されています。

免疫学市場を牽引しているのは、免疫疾患の有病率の上昇と、そうした疾患の治療に関する個人の意識の高まりです。また、世界各国の政府が科学・医療分野への支出を増やしていることも、免疫学市場の成長を後押ししています。バイオシミラーや個別化医療の動向は、現在市場に新たな展望をもたらしています。さらに、個別化免疫療法は、患者の免疫プロファイルが治療の指針となり、治療や投薬の効果を高めることから、今後主流になると予測されています。

しかし、免疫学において創薬は長期にわたるプロセスであり、研究室での研究に10～15年を要することが多いため、市場成長の妨げとなっています。加えて、新薬や治療法に関する厳しいコンプライアンス要件や承認手続きの長期化も、市場の大きな抑制要因となっています。例えば、米国食品医薬品局は、医薬品を上市する前に遵守しなければならない一連の長い規制を実施しています。この一連の規制には、前臨床試験、治験薬申請、3段階の臨床試験、新薬承認申請、そして最後に市販後調査が含まれます。医薬品メーカーは、医薬品の有効性と長期的な効果を保証するために、この一連の流れに従うことが義務付けられています。

セグメント別レビュー

免疫学市場は、製品タイプ、用途、エンドユーザー、地域に区分されます。製品タイプ別では、診断検査機器、バイオマーカー、バイオ医薬品に分類されます。用途別では、アレルギー・過敏症、自己免疫疾患、感染症、HIV・エイズ、その他に分類されます。エンドユーザー別では、病院・クリニック、製薬・バイオテクノロジー企業、診断研究所、その他に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。

主な調査結果

製品タイプ別では、バイオ医薬品分野が予測期間中優位を維持すると予測されます。

用途別では、自己免疫疾患分野が2033年までに高い市場シェアを獲得すると予測されます。

エンドユーザー別では、病院・診療所分野が予測期間中最高シェアになると予測されます。

地域別では、北米が2033年までに優位性を維持すると予測されています。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • クライアントの関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • 主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 IMMUNOLOGY市場：製品タイプ別

  • 市場概要
  • 診断検査機器
  • バイオマーカー
  • バイオ医薬品

第5章 免疫学市場：用途別

  • 市場概要
  • アレルギーと過敏症
  • 自己免疫疾患
  • 感染症
  • HIVおよびエイズ
  • その他

第6章 免疫学市場：エンドユーザー別

  • 市場概要
  • 病院・クリニック
  • 製薬・バイオテクノロジー企業
  • 診断研究所
  • その他

第7章 免疫学市場：地域別

  • 市場概要
  • 北米
    • 主な市場動向と機会
    • 米国免疫学市場
    • カナダ免疫学市場
    • メキシコ免疫学市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの免疫学市場
    • フランス免疫学市場
    • 英国免疫学市場
    • イタリア免疫学市場
    • スペイン免疫学市場
    • その他欧州免疫学市場
  • アジア太平洋
    • 主な市場動向と機会
    • 日本の免疫学市場
    • 中国免疫学市場
    • インド免疫学市場
    • オーストラリア免疫学市場
    • 韓国の免疫学市場
    • その他アジア太平洋の免疫学市場
  • ラテンアメリカ・中東・アフリカ
    • 主な市場動向と機会
    • ブラジル免疫学市場
    • サウジアラビア免疫学市場
    • 南アフリカの免疫学市場
    • その他のラテンアメリカ・中東・アフリカの免疫学市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • AbbVie Inc.
  • Johnson And Johnson
  • Pfizer Inc.
  • Novartis AG
  • Merck And Co., Inc.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Eli Lilly And Company
  • Gilead Sciences, Inc.
  • Sanofi
目次
Product Code: A298165

Immunology Market

The immunology market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.

Immunology is a branch of science involved in studying the immune system of an organism. Immune system is the defense mechanism of a living body which fights against infections, foreign substances, and diseases. Immunology finds applications in diverse disciplines of medicine, including oncology, organ transplantation, rheumatology, bacteriology, virology, parasitology, dermatology, and psychiatry.

The immunology market is driven by rise in prevalence of immunological diseases and surge in awareness among individuals regarding the treatment of such diseases. In addition, governments across the globe have increased their expenditure in the field of science and medicine, thereby augmenting the growth of the immunology market. Boost in the trend of biosimilars and personalized medicine is currently presenting new prospects for the market. Moreover, personalized immunotherapy is projected to become mainstream in the future as a patient's immune profile guides the treatment in this approach, hence elevating the effectiveness of the therapy and medications.

However, drug discovery is a lengthy process in immunology, which often requires 10-15 years of research in the laboratory, hence hampering the market growth. In addition, the stringent compliance requirements and the extended approval procedure of new drugs & treatments is a significant restraint for the market. For instance, the U.S. Food and Drug Administration has implemented a long series of regulations which is necessary to follow before releasing any drug in the market. This series involves preclinical testing, submission of investigational new drug application, three phases of clinical trials, submission of new drug application, and lastly post-market surveillance. Drug manufacturers are obliged to follow the sequence to ensure the efficacy and long-term effects of their medications.

Segment Review

The immunology market is segmented into product type, application, end user, and region. On the basis of product type, the market is divided into diagnostic testing equipment, biomarkers, and biopharmaceuticals. By application, it is classified into allergy & hypersensitivity, autoimmune disease, infectious disease, HIV & AIDS, and others. As per end user, it is categorized into hospitals & clinics, pharmaceutical & biotechnology companies, diagnostic laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the biopharmaceuticals segment is expected to maintain its dominance during the forecast period.

By application, the autoimmune disease segment is projected to garner a high market share by 2033.

As per end user, the hospitals & clinics segment is anticipated to be the highest shareholder during the forecast period.

Region wise, North America is predicted to maintain its dominance by 2033.

Competition Analysis

The major players operating in the global immunology market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company, Gilead Sciences, Inc., and Sanofi. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Diagnostic Testing Equipment
  • Biomarkers
  • Biopharmaceuticals

By Application

  • Allergy and Hypersensitivity
  • Autoimmune Disease
  • Infectious Disease
  • HIV and AIDS
  • Others

By End User

  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • AbbVie Inc.
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • Sanofi

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities

CHAPTER 4: IMMUNOLOGY MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Diagnostic Testing Equipment
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Biomarkers
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Biopharmaceuticals
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: IMMUNOLOGY MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Allergy And Hypersensitivity
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Autoimmune Disease
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Infectious Disease
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. HIV And AIDS
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: IMMUNOLOGY MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Pharmaceutical And Biotechnology Companies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Laboratories
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: IMMUNOLOGY MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Product Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Immunology Market
      • 7.2.6.1. Market Size and Forecast, By Product Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Immunology Market
      • 7.2.7.1. Market Size and Forecast, By Product Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Immunology Market
      • 7.2.8.1. Market Size and Forecast, By Product Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Product Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Immunology Market
      • 7.3.6.1. Market Size and Forecast, By Product Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Immunology Market
      • 7.3.7.1. Market Size and Forecast, By Product Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Immunology Market
      • 7.3.8.1. Market Size and Forecast, By Product Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Immunology Market
      • 7.3.9.1. Market Size and Forecast, By Product Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Immunology Market
      • 7.3.10.1. Market Size and Forecast, By Product Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Immunology Market
      • 7.3.11.1. Market Size and Forecast, By Product Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Product Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Immunology Market
      • 7.4.6.1. Market Size and Forecast, By Product Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Immunology Market
      • 7.4.7.1. Market Size and Forecast, By Product Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Immunology Market
      • 7.4.8.1. Market Size and Forecast, By Product Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Immunology Market
      • 7.4.9.1. Market Size and Forecast, By Product Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Immunology Market
      • 7.4.10.1. Market Size and Forecast, By Product Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Immunology Market
      • 7.4.11.1. Market Size and Forecast, By Product Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Product Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Immunology Market
      • 7.5.6.1. Market Size and Forecast, By Product Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Immunology Market
      • 7.5.7.1. Market Size and Forecast, By Product Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Immunology Market
      • 7.5.8.1. Market Size and Forecast, By Product Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Immunology Market
      • 7.5.9.1. Market Size and Forecast, By Product Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Johnson And Johnson
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Pfizer Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Novartis AG
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Merck And Co., Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Bristol-Myers Squibb Company
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Amgen Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Eli Lilly And Company
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Gilead Sciences, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Sanofi
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments